SCHEMBL6793154

SCHEMBL6793154

COc1cc2c(c(OC)c1OC)CCC(C=O)=C2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HSD17B3 P37058 1/20 0.38
KDM4E B2RXH2 2/20 0.38
POLB P06746 2/20 0.38
MAPT P10636 2/20 0.38
KMT2A Q03164 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
MEN1 O00255 1/20 0.38
TUBB4A P04350 3/20 0.36
TUBB P07437 3/20 0.36
TUBA3C P0DPH7 3/20 0.36
TUBA1B P68363 3/20 0.36
TUBA4A P68366 3/20 0.36
TUBB4B P68371 3/20 0.36
TUBB3 Q13509 3/20 0.36
TUBB2A Q13885 3/20 0.36
TUBB8 Q3ZCM7 3/20 0.36
TUBA3E Q6PEY2 3/20 0.36
TUBA1A Q71U36 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methylene Chloride SCHEMBL28111275 0.94 LMNA (0.36) LMNASMN1; SMN2HSD17B3KDM4EPOLB
SCHEMBL6783071 0.80 KDM4E (0.51) LMNASMN1; SMN2KDM4EPOLBKMT2A
SCHEMBL1589975 0.76 ALDH1A1 (0.44) SMN1; SMN2KDM4EMAPTTDP1ALDH1A1
SCHEMBL6787091 0.75 ATM (0.41) LMNASMN1; SMN2HSD17B3KDM4EPOLB
SCHEMBL7814302 0.74 TPMT (0.41) LMNAKDM4EPOLBMAPTKMT2A
SCHEMBL6794084 0.74 ALDH1A1 (0.55) LMNAKDM4EMAPTKMT2ATDP1
Ethoxycarbonyl Group SCHEMBL28016264 0.73 MAPT (0.33) LMNASMN1; SMN2KDM4EPOLBMAPT
SCHEMBL6785629 0.72 SMN1; SMN2 (0.35) LMNASMN1; SMN2KDM4EPOLBMAPT
SCHEMBL14823524 0.71 KDM4E (0.43) LMNAKDM4EPOLBMAPTKMT2A
SCHEMBL9621166 0.69 ATM (0.41) LMNASMN1; SMN2KDM4EPOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104649879-B Substituted benzene methylene 1,2,3,4-Tetrahydrooxonaphthalene analog derivative and preparation method, application 中国人民解放军第二军医大学 2017-01-04 CN claimed
CN-104649879-A Substituted benzylidene tetralone derivatives and preparation method and applications UNIV PLA 2ND MILITARY MEDICAL 2015-05-27 CN claimed
CN-106632050-B Benzo indazole analog derivative and preparation method thereof, application 中国人民解放军第二军医大学 2019-08-13 CN disclosed
CN-107011266-A Prodrug of benzo indazole analog derivative and preparation method thereof, application 中国人民解放军第二军医大学 2017-08-04 CN disclosed
CN-104649879-B Substituted benzene methylene 1,2,3,4-Tetrahydrooxonaphthalene analog derivative and preparation method, application 中国人民解放军第二军医大学 2017-01-04 CN disclosed
CN-104649879-A Substituted benzylidene tetralone derivatives and preparation method and applications UNIV PLA 2ND MILITARY MEDICAL 2015-05-27 CN disclosed
US-6828316-B2 Antiallergens KOWA CO., LTD. (JP) 2004-12-07 US disclosed
US-20020042414-A1 Diamide compound and medicine containing the same KOWA CO., LTD. (JP) 2002-04-11 US disclosed
US-6340682-B1 FOR THERAPY OF ALLERGIC IMMUNOLOGICAL DISEASE IS SELECTED FROM ASTHMA, ALLERGIC RHINITIS, INFLAMMATORY LARGE BOWEL DISEASE OR CONTACT DERMATITIS KOWA CO., LTD. (JP) 2002-01-22 US disclosed
EP-0926138-A1 DIAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME KOWA CO. LTD. (JP) 1999-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042414-A1 Diamide compound and medicine containing the same HRH4, HRH2, HRH1 LMNA 4686/4885SMN1; SMN2 4780/4885HSD17B3 1248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.